Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1441-1460 of 3,900 trials

Breast Cancer: GR1014 Gel for Radiation Skin Protection

We are studying whether GR1014 gel can help prevent skin damage during radiation therapy for localized breast cancer after lumpectomy. This trial compares the gel to a standard treatment to see which is more effective.

Radiation-Induced Dermatitis≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesDermatologyOncology

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Cemiplimab Immunotherapy Study

We are investigating if continuing cemiplimab treatment helps patients with oligometastatic NSCLC live longer without disease progression after initial therapy. This study compares the effects of cemiplimab to a placebo.

Non-small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Standard MedicinesOncology

Advanced Mesothelioma: Pembrolizumab and Dendritic Cell Vaccine

We are studying a combination of pembrolizumab and a personalized vaccine for patients with advanced mesothelioma who have not responded to earlier treatments. The goal is to see if this approach can improve outcomes for these patients.

Mesothelioma>2 yearsSafety phase (I)Oncology

Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Ovarian Stimulation Methods for Embryo Accumulation

We are comparing two approaches to ovarian stimulation in patients preparing for embryo testing. The goal is to see if one method produces more healthy embryos than the other.

Female InfertilityMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Erosive Esophagitis: Oral Pantoprazole for Kids and Teens

We are studying how well oral pantoprazole works for maintaining healing in children and teens aged 1 to 17 with erosive esophagitis. We also want to understand its safety and how well they tolerate the treatment.

Erosive Esophagitis6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteGastroenterologyPediatrics

Sedation in Preterm Infants: Dexmedetomidine vs. Midazolam

We are comparing two sedation methods for very preterm infants on mechanical ventilation to see which one helps with extubation time and overall safety. This study will help us understand the best approach for sedation in these vulnerable patients.

Infant Sedation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPediatrics

Triple-Negative Early Breast Cancer: Sacituzumab Govitecan with or without Pembrolizumab

We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.

Triple-Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Epidermolysis Bullosa Simplex: Apremilast Study

We are investigating whether apremilast can improve symptoms in patients over 6 years old with epidermolysis bullosa simplex. The study will also look at the safety of the treatment and how it affects quality of life.

Epidermolysis Bullosa Simplex3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyRheumatology

Heart Failure: Stopping Beta-Blockers

We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.

Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Ulcerative Colitis and Crohn’s Disease: Vedolizumab for Kids

We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.

Ulcerative ColitisCrohn's Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Advanced Malignancies: Testing DSB2455

We are assessing a new anti-cancer treatment, DSB2455, for patients with advanced malignancies. The goal is to understand how well it works when given alone.

Breast Cancer without Active Brain MetastasesProstate Cancer with Active Brain MetastasesOvarian Cancer without Active Brain Metastases>2 yearsSafety phase (I)Oncology

CDR404 for Solid Tumors

We are testing a new treatment called CDR404 in patients with specific solid tumors. The study aims to evaluate its safety and effectiveness in fighting cancer.

Solid Tumors>2 yearsSafety phase (I)Oncology

Refractory Focal Onset Epilepsy: BHV-7000 Study

We are testing a new medication, BHV-7000, to see if it can help reduce seizures in adults with refractory focal onset epilepsy. The study compares its effects to a placebo to evaluate safety and effectiveness.

Focal Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

BHV-7000 for Idiopathic Generalized Epilepsy

We are studying a new treatment for people with idiopathic generalized epilepsy who have generalized tonic-clonic seizures. The trial will compare its effects to a placebo to see if it helps reduce seizure frequency and is safe to use.

Idiopathic Generalized Epilepsy6-12 monthsEfficacy phase (II)Confirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyHematology

Perennial Allergic Rhinitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, to see if it helps adults with perennial allergic rhinitis experience fewer nasal symptoms. This study compares its effects to a placebo treatment.

Perennial Allergic RhinitisConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyOtolaryngologyPulmonology

Epidermolysis Bullosa Simplex: Diacerein 1% Ointment

We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.

Epidermolysis Bullosa Simplex1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology